Three Key Points to Prepare for an Early Phase Clinical Trial
Companies preparing for an early phase study must deal with an array of challenges and decisions for biometrics, pharmacovigilance and regulatory...
Most early phase studies focus on PK/PD, often performed in healthy volunteers, to
For most Bioavailability & Bioequivalence (BA-BE) studies, the objective is to
The scope of work undertaken ranges from
Medical writers need to have solid scientific training and experience in order to produce technical documents, and interpret and describe the results in a Clinical Study Report (CSR). Most frequently this entails a PhD or MD degree, with relevant doctoral or postgraduate qualifications, in a field of scientific research or a pharmaceutical setting. Some training in pre-clinical research or pharmacology is necessary for understanding the goals of the study, to hold discussions with Sponsor researchers and clinicians, and ultimately being able to write the protocol and other technical documents. A working knowledge of statistical concepts and methods is called for to understand the Statistical Analysis Plan and to write-up the results in the CSR.
Knowledge of regulatory requirements is needed to conduct trials and submit findings to various countries, such as US (FDA), EU (EMEA), Health Canada, India (CDSCO & DCGI), and Australia (TGA). Regulatory guidelines for the conduct and reporting of clinical trials differ from country to country. Although there are efforts to harmonize guidelines and regulations, differences exist in how to initiate clinical trials for a new drug, biologic or device, and apply for marketing authorization and approval. Timelines, documents, analyses needed may differ and a Medical Writer with experience in the country’s regulations can help make the task smoother.
Some practices can facilitate the handling of Early Phase Studies for the team and for the Medical Writer.
The Veranex Medical Writing/Regulatory Publishing team has successfully submitted more than 200 early phase studies. The group (formerly Quartesian) has an overall average of 12 plus years of experience, and demonstrated proficiency in handling these studies. Contact us to learn how we can help.
Companies preparing for an early phase study must deal with an array of challenges and decisions for biometrics, pharmacovigilance and regulatory...
First-in-Human studies are a discovery point, which can decide the fate of a compound as well as lay the groundwork for subsequent phases of a...
It should come as no surprise that conducting a clinical trial is expensive. Just how expensive depends on the phase and design of the trial, with...